Management of Hematuria in Patients on Anticoagulation Therapy

Assessment and Management of Bleeding Severity

The American College of Cardiology recommends that for a patient on apixaban with bright red blood in urine, apixaban should be temporarily discontinued, supportive care should be provided, and the severity of bleeding should be assessed to determine if reversal agents are needed 1
Major bleeding criteria include bleeding at a critical site, hemodynamic instability, or a hemoglobin decrease ≥2 g/dL or administration of ≥2 units of blood, as defined by the American College of Cardiology 1
For major bleeding, the American College of Cardiology recommends stopping apixaban immediately, providing local therapy/manual compression if applicable, providing supportive care and volume resuscitation, assessing for and managing comorbidities that could contribute to bleeding, and considering surgical/procedural management of the bleeding site 1, 2
For life-threatening bleeding, the American College of Cardiology suggests considering the administration of reversal agents such as prothrombin complex concentrates (PCCs) or andexanet alfa, a specific reversal agent for apixaban 1, 2

The American College of Cardiology recommends considering whether there is a clinical indication for continued anticoagulation, whether the source of bleeding has been identified and addressed, and whether the patient is at high risk of rebleeding before restarting anticoagulation 1
Once bleeding is controlled and the patient is stable, apixaban can be resumed at least 6 hours after bleeding has been controlled, according to Anaesthesia guidelines 3
The American College of Cardiology suggests considering alternative anticoagulation options if apixaban is contraindicated due to the bleeding event 1

The American College of Chest Physicians recommends evaluating the indication for anticoagulation and assessing the patient's thrombotic risk versus bleeding risk when considering resumption of anticoagulation 4
Severe renal impairment (CrCl <15 mL/min) is a relative contraindication to continuing apixaban, and renal function should be assessed using the Cockcroft-Gault formula to calculate creatinine clearance 5

If bleeding is controlled and anticoagulation is essential, apixaban can be resumed at least 6 hours after hemostasis is achieved, according to the Anaesthesia journal 6
The American College of Chest Physicians suggests considering alternative anticoagulation strategies, such as warfarin with careful INR monitoring or left atrial appendage closure, if apixaban is deemed too high-risk 4
For unprovoked VTE, stopping anticoagulation significantly increases recurrent VTE risk, and aspirin 81-100 mg daily provides modest protection if anticoagulation is contraindicated, as recommended by the American College of Chest Physicians 7, 4

Annual reassessment is mandatory if extended anticoagulation is continued, with particular attention to changes in renal function, bleeding history, and fall risk in elderly patients, according to the Chest journal 7